Echinocandins - structure, mechanism of action and use in antifungal therapy

被引:142
作者
Szymanski, Mateusz [1 ]
Chmielewska, Sandra [2 ]
Czyzewska, Urszula [1 ]
Malinowska, Marta [3 ]
Tylicki, Adam [1 ]
机构
[1] Univ Bialystok, Dept Microbiol & Biotechnol, Lab Cytobiochem, K Ciolkowskiego 1J, PL-15245 Bialystok, Poland
[2] Univ Bialystok, Doctoral Sch Exact & Nat Sci, Bialystok, Poland
[3] Univ Bialystok, Dept Organ Chem, Lab Nat Prod Chem, Bialystok, Poland
关键词
Anidulafungin; caspofungin; micafungin; rezafungin; drug resistance; chemical modification; IN-VITRO ACTIVITY; INVASIVE CANDIDIASIS; FUNGAL-INFECTIONS; REZAFUNGIN CD101; CLINICAL ISOLATE; CASPOFUNGIN; MICAFUNGIN; ANIDULAFUNGIN; SUSCEPTIBILITY; PHARMACOKINETICS;
D O I
10.1080/14756366.2022.2050224
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well. The action of echinocandins is based on the inhibition of beta-(1,3)-d-glucan synthesis that builds the fungal cell wall. Caspofungin, micafungin, anidulafungin and rezafungin are semi-synthetic cyclic lipopeptides. Their specific chemical structure possess a potential to obtain novel derivatives with better pharmacological properties resulting in more effective treatment, especially in infections caused by Candida and Aspergillus species. In this review we summarise information about echinocandins with closer look on their chemical structure, mechanism of action, drug resistance and usage in clinical practice. We also introduce actual trends in modification of this antifungals as well as new methods of their administration, and additional use in viral and bacterial infections.
引用
收藏
页码:876 / 894
页数:19
相关论文
共 145 条
[1]   Echinocandins: The Expanding Antifungal Armamentarium [J].
Aguilar-Zapata, Daniel ;
Petraitiene, Ruta ;
Petraitis, Vidmantas .
CLINICAL INFECTIOUS DISEASES, 2015, 61 :S604-S611
[2]   Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method [J].
Arendrup, M. C. ;
Meletiadis, J. ;
Zaragoza, O. ;
Jorgensen, K. M. ;
Marcos-Zambrano, L. J. ;
Kanioura, L. ;
Cuenca-Estrella, M. ;
Mouton, J. W. ;
Guinea, J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (11) :1200-1204
[3]   Echinocandin resistance: an emerging clinical problem? [J].
Arendrup, Maiken C. ;
Perlin, David S. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) :484-492
[4]   Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside [J].
Aruanno, Marion ;
Glampedakis, Emmanouil ;
Lamoth, Frederic .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
[5]   Pharmacology of systemic antifungal agents [J].
Ashley, Elizabeth S. Dodds ;
Lewis, Russell ;
Lewis, James S. ;
Martin, Craig ;
Andes, David .
CLINICAL INFECTIOUS DISEASES, 2006, 43 :S28-S39
[6]   The echinocandins: three useful choices or three too many? [J].
Bal, A. M. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (01) :13-18
[7]   Discovery and development of first in class antifungal caspofungin (CANCIDAS®)-A case study [J].
Balkovec, James M. ;
Hughes, David L. ;
Masurekar, Prakash S. ;
Sable, Carole A. ;
Schwartz, Robert E. ;
Singh, Sheo B. .
NATURAL PRODUCT REPORTS, 2014, 31 (01) :15-34
[8]   Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance [J].
Ben-Ami, Ronen ;
Garcia-Effron, Guillermo ;
Lewis, Russell E. ;
Gamarra, Soledad ;
Leventakos, Konstantinos ;
Perlin, David S. ;
Kontoyiannis, Dimitrios P. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (04) :626-635
[9]   Colistin interacts synergistically with echinocandins against Candida auris [J].
Bidaud, A. L. ;
Djenontin, E. ;
Botterel, F. ;
Chowdhary, A. ;
Dannaoui, E. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (03)
[10]   Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision [J].
Bongomin, Felix ;
Gago, Sara ;
Oladele, Rita O. ;
Denning, David W. .
JOURNAL OF FUNGI, 2017, 3 (04)